Flurazepam Hydrochloride Capsule Shortage

Source: FDA · United States

Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Flurazepam Hydrochloride capsules remain listed as a current shortage by the FDA, though all presentations are available from the sole manufacturer.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on May 26, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Flurazepam Hydrochloride.

What's in Shortage

Flurazepam Hydrochloride Capsule (brand name: FLURAZEPAM HYDROCHLORIDE) is listed in current shortage. The dosage form is Capsule and the therapeutic categories are Neurology and Other. The shortage was first posted on 08/03/2022 and last updated on 05/19/2026.

Which Manufacturers Are Affected

  • Chartwell Molecular Holdings LLC: Available for Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30); contact 845-268-5000 Ext. 510
  • Chartwell Molecular Holdings LLC: Available for Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30); contact 845-268-5000 Ext. 510
  • Chartwell Molecular Holdings LLC: Available for Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90); contact 845-268-5000 Ext. 510
  • Chartwell Molecular Holdings LLC: Available for Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90); contact 845-268-5000 Ext. 510

Why There's a Shortage

No specific reason was provided in the FDA Drug Shortage Database.

What Patients Should Do

Patients should talk to their pharmacist, ask about availability or alternatives, and contact the manufacturer if needed. Always consult your healthcare provider before making any changes to your medication.

Source

FDA Drug Shortage Database

Original source: FDA Official Notice ↗

All Drug Shortages →

Nationwide notices with similar length or severity timing 8

Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
Flurazepam Hydrochloride capsules remain listed as a current shortage by the FDA, though all presentations are available from the sole manufacturer.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "low" severity. No immediate action required, but stay aware.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.